Bimagrumab

The anti-obesity medication (AOM) market is evolving, with 2025 set to be a pivotal year. Key developments include redefining obesity diagnosis, advancing AOM innovation, and expanding reimbursement. The market sees intense competition, with Lilly and Novo Nordisk leading. Real-world data on AOM effectiveness and patient outcomes will shape future strategies.

Novo Nordisk and Eli Lilly's weight loss treatments, Wegovy and Mounjaro, have seen skyrocketing sales, significantly boosting their share prices. The obesity treatment market, expected to reach $60 billion in a decade, has spurred R&D across the pharma industry, with companies racing to develop more effective or convenient treatments, including oral options. Pfizer faced setbacks in clinical trials for an oral treatment, while others explore alternative approaches. Deal-making is intensifying, with companies like Roche and AstraZeneca acquiring weight loss programs to strengthen their portfolios. The market's growth is driven by the urgent need to address obesity, societal pressures, and the potential for aesthetic weight loss, indicating a vast market potential.

Weight loss in obesity treatment primarily reduces fat mass over fat-free mass, with minimal sarcopenia risk for most adults. However, GLP-1 therapy's impact on older adults' muscle mass requires further study.

Merck secures global rights to Hansoh Pharma's oral GLP-1 receptor agonist, HS-10535, for obesity treatment, with a $112M upfront payment and up to $1.9B in milestones. GLP-1 drugs, popular for diabetes and obesity, mimic GLP-1 hormone for weight loss and health benefits. The obesity market, driven by global health concerns, is projected to reach $100B by 2030, with major players like Lilly and Novo Nordisk expanding their portfolios.

GLP-1 drugs like Wegovy and Zepbound can lead to significant weight loss but may also cause muscle loss. Researchers are concerned about the impact on muscle mass and function, which can affect health and mobility. Strategies to preserve muscle include a protein-rich diet, regular exercise, and potentially using drugs that prevent muscle loss.

Eli Lilly and Laekna collaborate on an obesity drug, LAE102, targeting weight loss and muscle preservation. This move intensifies competition in the $150B obesity treatment market, dominated by Lilly and Novo Nordisk. Other companies like Regeneron and Scholar Rock are also developing muscle-preserving treatments, reflecting a growing focus on maintaining muscle mass during weight loss.

Weight-loss drugs like Wegovy and Ozempic are changing the world in unexpected ways, influencing fashion, Hollywood, social lives, the weight-loss industry, food industry, gyms, and even airlines, while also raising questions about mental health and body positivity.

New companies aim to challenge Eli Lilly and Novo Nordisk's dominance in the GLP-1 weight-loss drug market, projected to reach $200 billion by 2031. Emerging competitors like Roche, Amgen, Pfizer, and AstraZeneca focus on enhanced efficacy and convenience to disrupt the market. By 2029, 16 new drugs are expected to enter the market, adding $70 billion to the segment. Despite pricing challenges and limited international penetration, GLP-1 drugs are expected to see significant usage in the U.S., with Novo and Lilly maintaining a strong market presence through pipeline advancements.

Novo Nordisk and Eli Lilly dominate the obesity drug market with GLP-1 agonists, achieving multi-billion sales in 2024. Their drugs, including Mounjaro and Wegovy, lead in treating Type 2 diabetes and obesity, with the market expected to grow significantly. Other companies are advancing obesity treatments, indicating a competitive and expanding market.

Semaglutide and tirzepatide, FDA-approved for obesity, show promise with tirzepatide achieving up to 22% weight loss. Both regulate appetite, sharing similar side effects. Future obesity treatments may include novel monotherapies, combinations, and oral formulations, aiming for greater efficacy and tolerability. Gubra leads in anti-obesity drug development, with GUBamy entering Phase 1 trials.